<h1>CAR T therapy access expanded via 0% EMI bridge financing and value based payment up to ten lakh rupees tied to outcomes.</h1> A biotech and a healthcare data/AI firm partnered to expand access to an autologous CAR T therapy by offering eligible patients 0% interest EMI bridge financing up to ten lakh rupees and a value based offering up to ten lakh rupees linked to clinical eligibility and outcomes; the lead product holds Market Authorisation from the national regulator and the data partner will support outcome measurement and program administration at select facilities to improve affordability and uptake.